A University of California, San Diego-led team from the Alzheimer’s Disease Neuroimaging Initiative has reported that in long-term imaging studies, objective subtle cognitive deficits (obj-SCD) preceded amyloid deposition in longitudinal imaging studies.
How organisms age, and what determines their lifespan, is one of the basic questions of biology. It is also a major area of biopharmaceutical interest. Partly, this is because most people want to delay shuffling off this mortal coil for as long as possible.
A mitochondrial glutamine transporter variant is a key regulator of glutamine metabolism and metabolic reprogramming in cancer cells, and targeting such transporters could be a new strategy for controlling tumor growth.
A reference genome from the Indian cobra compiled in an international collaborative study should lead to the development of new safer and more effective antivenoms, while the elucidated genome and predicted associated proteome may be a powerful platform for studies of venomous snakes.
Amyloid and tau proteins are both involved in the disease pathology of Alzheimer’s disease. The diagnostic and treatment research focus has long been on amyloid, which has proven almost entirely fruitless after decades of effort. But tau is becoming better understood, as investigational tau imaging agents offer the ability to visualize its presence in the brain.
A mitochondrial glutamine transporter variant of the SLC1A5 gene is a key regulator of glutamine metabolism and metabolic reprogramming in cancer cells, and targeting such transporters could be a new strategy for controlling tumor growth, Korean researchers reported online in the Dec. 19, 2019, edition of Cell Metabolism.
RSS
